Objective To detect patients with cancer of the stomach cancer tissue and serum Periostin protein expression of the situation,the preliminary explore its clinical significance.Methods Selected 60 cases of our hospital diagnosed as gastric carcinoma patients with carcinoma tissue samples,tissue adjacent to carcinoma specimens and serum,and choose 60 cases of healthy check-up serum specimens at the same time.Classified all patients according to clinical classification factors,inclu-ding age,sex,TNM stage,degree of infiltration,lymph node metastasis and pathological grading,immunohistochemical meth-od determination of Periostin in gastric cancer and adjacent tissue protein expression,enzyme-linked immunoassay detection in patients with gastric cancer patients and normal serum Periostin protein content.Results The method of ELISA to detect gastric cancer patients serum Periostin protein level was 46.76.4 ng/ml,and healthy crowd Periostin protein levels was 23.1 ±4.5 ng/ml,statistically significant difference (t= 7.34,P<0.05).Immunohistochemical methods showed that Periostin in patients with cancer of the stomach cancer tissue protein positive rate was (73.2±5.4)%,positive rate of (33.4±6.5)%in the tissue adjacent to carcinoma,statistically significant difference (t=8.52,P<0.05).Ⅲ~Ⅳ period patients serum Periostin protein level was 64.9±6.3 ng/ml,Ⅰ~Ⅱ period patients serum Periostin protein level was 41.6±4.1 ng/ml, statistically significant difference (t=9.17,P< 0.05).Periostin protein inⅢ~Ⅳ positive rate was 67.8% in patients with carcinoma tissue,Ⅰ~ phase Ⅱ positive rate was 52.9%,statistically significant difference (t=9.64,P<0.05).According to infiltrate the classification:T3,T4 patients serum Periostin protein level was 61.9±6.6 ng/ml,T1 and T2 patients serum Periostin protein level was 44.6±3.7 ng/ml,statistically significant difference (t=8.24,P<0.05).Periostin protein in T3 and T4 positive rate was 6 6.2% in patients with carcinoma tissue,T1 and T2 positive rate was 5 1.4%,statistically signifi-cant difference (t=7.58,P<0.05).Lymph node metastasis patients serum Periostin protein level was 65.2±4.3 ng/ml, without metastasis in patients with serum Periostin protein level was 42.6±3.2 ng/ml,statistically significant difference (t=7.63,P<0.05).Periostin protein in the tissue of carcinoma patients with lymph node metastasis group positive rate was 60.8%,no transfer of positive rate was 37.5%,statistically significant difference (t=8.56,P<0.05).Conclusion Periostin protein expression in patients with gastric cancer tissue and serum was significantly higher than that of healthy people,and to a certain extent is proportional to the illness,Periostin protein is a predictable stomach occurrence,lesion degree of poten-tial biological indicators.

Allicin,which contains rich sulfide ,is provided for prevention and treatment of tumor ,anti in-flammation,prevention and treatment of cardiovascular diseases ,improving immunity and so on .Studies show that allicin can not only prevent many types of cancer ,but also has obvious inhibitory effect on tumor .The mechanism is related with antioxidant effects ,reducing the invasion of tumor cells ,inhibiting the proliferation of tumor cells , inducing tumor cell apoptosis and directly killing the tumor cells .This paper reviews the research progresses on antitumor allicin .

Porcine reproductive and respiratory syndrome is caused by the PRRS virus(PRRSV), which has six structural proteins(GP2, GP3, GP4, GP5, M and N). GP5 and N protein are important targets for serological detection by enzyme-linked immunosorbent assay(ELISA)and other methods. Toward this goal, we developed an indirect ELISA with recombinant GP5 antigens and this method was validated by comparison to the LSI PRRSV-Ab ELISA kit. The results indicated that the optimal concentration of coated recombinant antigen was 0.2 μg/well for a serum dilution of 1:40. The rate of agreement with the LSI PRRSV-Ab kit was 88.7%(266/300). These results support the potential use of recombinant GP5 as an antigen for indirect ELISA to detect PRRSV antibodies in pigs.

Objective To investigate the effects of garlicin capsule on immune function in patients with breast cancer undergoing chemotherapy??Methods Form April 2018 to October 2018,62 patients with breast cancer were treated by operation in Tangshan People′s Hospital and pathologically diagnosed as breast cancer??Random number table method was used to divide the patients into treatment group and control group, with 31 cases in each group??The treatment group was given garlicin capsule combined with EC regimen( the first day( epirubicin hydrochloride injection 90 mg／m2+ cyclophosphamide 90 mg／m2 ) ,21 days for one cycle,four consecutive cycles), while the control group was given EC regimen alone for 4 courses??The occurrence of adverse reactions was recorded??T lymphocyte subsets were detected before and after treatment to evaluate the immune function of the body??Results There was no significant difference in the number of adverse reactions between the two groups after treatment ( Seventy in the treatment group and 69 in the control group) ( P＞0??05)??The levels of CD3+, CD4+, CD8+ and CD4+／CD8+ were ( 53??76 ± 4??29)%, (40??19 ±3??71)%,( 28??61 ± 2??75)% and ( 1??41 ± 0??16) in the treatment group before chemotherapy, respectively??While after chemotherapy were ( 52??41 ± 4??44)%, ( 39??49 ± 4??06)%, ( 28??70 ± 2??76)% and (1??35± 0??94), respectively??The levels of CD3+, CD4+, CD8+ and CD4+／CD8+ were ( 54??35 ± 4??09)%, (40??70± 4??09 )%, ( 27??62 ± 3??60 )% and ( 1??49 ± 0??24 ) in the control group before chemotherapy, respectively??While after chemotherapy were ( 44??27 ± 6??67)%, ( 35??39 ± 4??96)%, ( 30??48 ± 3??43)% and (1??17±0??20)??After treatment,the levels of CD3+,CD4+,CD4+／ CD8+ decreased and CD8+ increased,but there had no significant difference( P＞0??05)??After treatment,CD3+( decreased from( 54??35 ± 4??09)% to (44??27 ± 6??67 )%), CD4+( decreased from ( 40??70 ± 4??09 )% to ( 35??39 ± 4??96 )%), CD4+／CD8+ ((decreased from (1??49±0??24) to (1??17±0??20)),the difference was statistically significant( t value was 7??17,4??60,5??71,－3??02,P value was 0??000,0??000,0??002,0??000)??Compared with control group,the levels of CD3+、CD4+、CD4+／ CD8+in treatment group increased and CD8+decreased significantly (all P＜0??01)??Conclusion Garlicin capsule can improve the depression of immune function caused by chemotherapy??

Objective To investigate the clinical significance of individualized neoadjuvant chemotherapy for renal carcinoma to reduce side effects under the guidance of gene detection.Methods From January 2011 to March 2014,two hundred and twelve patients with renal carcinoma treated in Cangzhou Central Hospital were enrolled in the study and randomly divided into the gene detection group (102 cases) and non-gene detection group (110 cases).The gene detection group was detected by the real time fluorescence quantitative (RT-PCR) method and the drug sensitivity test was carried out,and the patients were given neoadjuvant chemotherapy based on the results of drug sensitivity test.The patients in the non-gene detection group were treated with the national comprehensive cancer network (NCCN) experience regimen.The incidence of chemotherapy side effects was compared between the two groups.Results The 1 year survival rate of the gene test group was higher than that in the non-gene detection group (87.25％ (89/102) vs.77.27％ (85/ 110),x2 =4.67,P＜0.05),and the 3 year survival rate increased (70.58％ (72/102) vs.64.54％ (71/110),x2 =4.510,P＜ 0.05) as well,the differences were statistically significant (P ＜ 0.05).The incidence of liver injury in the gene detection group was 17.64％ (18/102),which was lower than that in the control group 30％ (33/110),the difference was statistically significant (x2 =4.42,P ＜ 0.05).In the gene detection group,the incidence of leukocyte 3～4 level inhibition was 27.5％ (28/102),which was higher than that in the non-gene detection group 21.8％ (24/110).The difference was statistically significant (x2 =4.940,P ＜ 0.05).Conclusion Genetic polymorphisms detection is a guide to the application of tumor sensitive drugs in the individualized neoadjuvant chemotherapy of renal carcinoma.It can improve the therapeutic effect,and also reduce the occurrence of liver injury caused by side effects of chemotherapy and has high clinical application value.

Background and objective Epidermal growth factor receptor (EGFR) and KRAS gene are important driver genes of non-small cell lung cancer (NSCLC).The studies are mainly focused on detection ofEGFR gene for advanced NSCLC,and the mutation feature of EGFR and KRAS gene in early NSCLC tissue is unknown.This study aims to investigate the mutations of EGFR and KRAS gene in NSCLC,and the relationship between the genotype and clinicopathologic features.Methods The hotspot mutations in EGFR and KRAS gene in 754 tissue samples of stage Ⅰ-Ⅲa NSCLC from Department of Pathology,Peking Union Medical College Hospital were detected by modified amplification refractory mutation system (ARMS) real-time PCR kit,and analyzed their correlation with clinical variables.Results The hotspot mutation rates in EGFR and KRAS were 34.5％ and 13.1％ respectively,and there were EGFR-KRAS double mutations in 3 samples.The mutation rate of EGFR was higher in females than that in males (39.5％ vs 29.4％,P=0.076),significantly increased in adenocarcinomas (38.7％) compared to that in the other forms of NSCLC (P＜0.01),but still lower than that reported in some Asian studies of advanced adenocarcinoma (-50％).Meanwhile,the mutation rate of KRAS was remarkably higher in males than that in females (16.6％ vs 9％,P=0.048),increased in adenocarcinomas compared to that in the other forms of NSCLC,but the difference was not significant (P=0.268).Samples harbored EGFR mutation were younger than those harbored KRAS mutation (P=0.031,5),and had significant difference in gender between the two groups (P＜0.01).Conclusion The mutation rate of EGFR in stag Ⅰ-Ⅲa NSCLC patients was lower than that in advanced NSCLC patients.And the percentage of the NSCLC patients with EGFRKRAS double mutations is 0.9％.